YUTONG LIU1, Saumi Mathews2, Ed Makarov2, Lili Guo2, Mariano Uberti1, Balasrinivasa Sajja1, Larisa Poluektova2, Howard Gendelman2, and Santhi Gorantla2
1Radiology, University of Nebraska Medical Center, Omaha, NE 68198, NE, United States, 2Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68198, NE, United States
Synopsis
In this
study, we performed DTI and MRS on a newly created mouse model of brain HIV
infection. MRS results showed neuronal damage on hippocampus, and DTI showed diffuse
neuroinflammation caused by HIV infection. White matter changes was also observed
using DTI.
Introduction
Neurological deficits commonly follow progressive
human immunodeficiency virus (HIV) infection. A principal biomarker that has
successfully tracked the onset and progression of those deficits is magnetic resonance
imaging (MRI) in human and animal disease models (1, 2). In prior works changes
in diffusion tensor imaging (DTI) were shown coordinate with
immunohistochemistry in demonstrating inflammatory responses linked to
HIV-associated neuronal damage. N-acetyl aspartate (NAA) and creatine measured
using magnetic resonance spectroscopy (MRS) correlated with neuronal and glial
impairments. To extend these works a
novel mouse model of neuroHIV was created that contains the principal human
virus target cell, the microglia. These animals express the human IL-34 through
a cytomegalovirus promoter and following hematopoietic stem cells (HSC)
transplantation both lymphoid and brain tissues are humanized (3). DTI and MRS
studies were performed on these mice following HIV infection to determine the
extent of neural injuries that best reflect the human conditionMaterials and Methods
NOD.Cg-PrkdcscidIl2rgtm1SugTg(CMV-IL34)1/Jic
(NOG-hIL34) mice were intrahepatically transplanted at birth with human
umbilical cord blood CD34+ hematopoietic stem cells. Reconstitution of the
human immune system was confirmed by flow cytometry performed on the peripheral
blood. At 5 months of age mice were
infected intraperitoneally with HIV-1BAL and plasma viral loads were
measured at 12 weeks. Viral levels ranged from 105 to 106
HIV RNA copies/ml. MRI was performed on 6 control uninfected and 4 infected
mice using a 7 Tesla ParaVison 6.01 small animal scanner (Bruker PharmaScan
70/16, Billerica, MA). A Bruker made mouse head quadrature RF coil was employed.
Respiration and body temperature were monitored. Single voxel localized spectra
were acquired on the cerebral cortex, hippocampus and cerebellum using
semiLaser sequence. DTI measures were acquired using 4-segment spin-echo echo-planar
imaging with 12 diffusion and b = 800 s/cm2. MRS data were expressed
as a percentage of the sum of all metabolites. Apparent diffusion coefficient
(ADC) and fractional anisotropy (FA) were calculated using DiffusionToolkit (http://trackvis.org/dtk/)
and measured on cortex, hippocampus, cerebellum, hippocampus, striatum and
thalamus by brain subregion analysis. Results
NAA levels
were reduced in the hippocampus of infected mice as compared to controls
(Figure 1). ADC increased in infected mice in the cortex, hippocampus,
hippocampus, striatum and thalamus (Figure 2B). FA increased on cerebellum and
striatum (Figure 2B). Discussion
Measurements
of NAA, ADC and FA demonstrate that these infected mice show critical parallel
imaging biomarkers common during human HIV infections. For example, hippocampal
NAA reductions supports the types of neuronal dysfunction and consequent memory
loss that is seen commonly in this brain subregions during progressive viral
infection. Increased ADC reflects diffuse neuroinflammation. Increased FA in
infected mice that suggests white matter abnormalities that follow viral
infection. These results begin to unravel key neuropathobiological features of
microglial infection that can be followed through sensitive bioimaing
techniques.Acknowledgements
This study was partially supported by NIH P01 DA028555, R21 DA041018, R24 OD018546, R01 AG043540.References
1. Boska et
al. Molecular Neurodegeneration 2014.
2. Bade et
al. Mol Neurobiol. 2016.
3. Mathews
et al. Molecular Neurodegeneration 2019.